FDA approves NRx preservative-free ketamine injection amid US hospital supply shortage

The FDA has approved NRx Pharmaceuticals' preservative-free generic ketamine injection, adding a US-manufactured supply option during an ongoing shortage of injectable ketamine.
The abbreviated new drug application covers a preservative-free ketamine formulation manufactured with Nephron Pharmaceuticals using blow-fill-seal technology and formulated without the preservative benzethonium chloride.
NRx reported that commercial supply was available following the 30 October approval announcement, although a specific launch date was not confirmed, and the decision applies to established anaesthesia uses rather than the company's separate investigational depression programme.
Field | Content |
Article Type | Approvals |
Company | NRx Pharmaceuticals |
Manufacturing Partner | Nephron Pharmaceuticals |
Product | Preservative-free generic ketamine injection |
Active Ingredient | Ketamine |
Product Type | Generic injectable medicine |
Formulation | Preservative-free injection |
Excluded Preservative | Benzethonium chloride |
Manufacturing Technology | Blow-fill-seal |
Manufacturing Geography | United States |
Regulator | U.S. Food and Drug Administration |
Approval Type | Abbreviated new drug application approval |
Approval Announcement Date | 30 October 2026 |
Approved Therapeutic Use | Established ketamine anaesthesia uses |
Therapeutic Area | Anaesthesia |
Administration Route | Injection |
Supply Context | Ketamine injection listed on the FDA drug shortage list at the time of the announcement |
Commercial Supply Status | NRx reported commercial supply on hand |
Confirmed Commercial Launch Date | Not confirmed in supplied summary |
Investigational Depression Programme | Separate from the approved generic anaesthesia product |
Depression Indication Approval | No depression indication approval established by this announcement |
Geographic Scope | United States |
What Happened | The FDA approved an abbreviated new drug application for NRx's preservative-free generic ketamine injection. |
Why It Matters | The approval adds a domestically manufactured injectable ketamine supply option during a reported US drug shortage. |
Manufacturing Significance | The product uses blow-fill-seal technology and excludes benzethonium chloride. |
Key Takeaway | NRx secured FDA approval for a preservative-free generic ketamine product for established anaesthesia uses, not for its investigational depression programme. |
What to Watch | Confirmed commercial launch, hospital distribution, production capacity, shortage-list status and product availability. |
Primary Source | NRx Pharmaceuticals |
Primary Source URL | https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-nasdaqnrxp-receives-fda-approval |
Relevant Date | 30 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comentarios